- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT02543541
A Pilot Study of Structured Palliative Care for Patients Enrolled on Phase I Clinical Trials
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
Primary Objective(s): To assess symptoms, adverse events, duration on study, reason for study discontinuation, and quality of life among patients participating in phase I clinical trials who receive structured palliative care, and those who receive standard supportive care. Duration on study will serve as the primary objective for sample size determination.
Secondary Objective(s):
1. To describe the quantity (e.g. hours), type, and cost of palliative care personnel services used by patients and caregivers receiving structured palliative care.
Exploratory:
- To compare adverse event profiles, duration on study, and quality of life between patients who receive structured palliative care and those receiving standard supportive care.
- To compare caregiver burden and quality of life between the study arms.
Tipo di studio
Iscrizione (Effettivo)
Fase
- Non applicabile
Contatti e Sedi
Luoghi di studio
-
-
Ohio
-
Cleveland, Ohio, Stati Uniti, 44106
- Case Comprehensive Cancer Center
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Patient Inclusion Criteria:
- Patients must be enrolled in a Phase 1 clinical trial and be within 2 weeks of starting the experimental therapy or intervention.
- Patients are eligible to enroll on this study with or without the enrollment of their caregiver.
Patient Exclusion Criteria:
- Patients diagnosed with a hematologic malignancy.
Caregiver Inclusion Criteria:
- Any caregiver is considered eligible for this study; The caregiver is the person identified by the patient as the one who provides the most regular physical and/or emotional support.
- Caregivers must be willing to complete surveys at baseline and on monthly basis.
Caregiver Exclusion Criteria:
- Caregivers who are solely professional, paid caregivers
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Terapia di supporto
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Comparatore attivo: Standard Supportive Care
|
Supportive care for the patient and caregiver will be provided by the treating oncologist.
|
|
Sperimentale: Structured Supportive Care
|
Supportive care for the patient and caregiver will be provided by the outpatient palliative care team which includes clinicians with specialized palliative care training, social workers, spiritual care specialists and mental health clinical nurse specialist.
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Average total MSAS score
Lasso di tempo: Up to 6 months
|
Assessment of patient burden
|
Up to 6 months
|
|
Average total FACT-G score
Lasso di tempo: Up to 6 months
|
Measure patient quality of life
|
Up to 6 months
|
|
Reason for study discontinuation (Patient reported outcome)
Lasso di tempo: Up to 6 months
|
Measure of central tendency for why patients discontinued the phase I study.
Patient reported outcomes for reason for study discontinuation will be qualitatively assessed
|
Up to 6 months
|
|
Duration on Study
Lasso di tempo: Up to 6 months
|
Measure of central tendency of the duration patients were on the phase I study.
Duration on study will serve as the primary objective for sample size determination
|
Up to 6 months
|
|
Adverse events
Lasso di tempo: Up to 6 months
|
Measure of central tendency of adverse events.
AE will be described and further categorized as modifiable (primary symptom experience) and non-modifiable (laboratory abnormalities).
The influence of adverse events on study outcomes particularly duration on study and reason for study discontinuation will be assessed.
An exploratory weighted adverse event score will be calculated using the equation: adverse event score = ∑ (NAE * GAE) where N denotes the adverse event number, G denotes grade, AE denotes adverse event.
These scores will be compared between study arms
|
Up to 6 months
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Mean number of hours of palliative care services
Lasso di tempo: Up to 6 months
|
Mean number of hours utilized by patients and caregivers who received structured palliative care.
This analysis will be descriptive, reporting measures of central tendency
|
Up to 6 months
|
|
Type of palliative care services
Lasso di tempo: Up to 6 months
|
Measure of central tendency for the type of palliative care services utilized by patients and caregivers who received structured palliative care.
This analysis will be descriptive, reporting measures of central tendency
|
Up to 6 months
|
Altre misure di risultato
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Frequency of adverse events of patients receiving structured and usual supportive care
Lasso di tempo: Up to 6 months
|
Up to 6 months
|
|
|
Average days on study
Lasso di tempo: Up to 6 months
|
Up to 6 months
|
|
|
Change in FACT-G score
Lasso di tempo: From baseline to last contact, up to 6 months
|
Change in patient symptom burden when compared to baseline between patients who received structured palliative care and those who received standard supportive care
|
From baseline to last contact, up to 6 months
|
|
Change in MSAS score
Lasso di tempo: From baseline to last contact, up to 6 months
|
Change in quality of life when compared to baseline between patients who received structured palliative care and those who received standard supportive care
|
From baseline to last contact, up to 6 months
|
|
Change in CRA score
Lasso di tempo: From baseline to last contact, up to 6 months
|
Change in caregiver burden when compared to baseline between those who received structured palliative care and those who received standard supportive care
|
From baseline to last contact, up to 6 months
|
|
Change in QOLLTI-F score
Lasso di tempo: From baseline to last contact, up to 6 months
|
Change in caregiver quality of life as assessed through change in QOLLTI-F score when compared to baseline between those who received structured palliative care and those who received standard supportive care
|
From baseline to last contact, up to 6 months
|
Collaboratori e investigatori
Sponsor
Investigatori
- Investigatore principale: Michelle Treasure, MD, Metrohealth Medical Center and Case Comprehensive Cancer Center
Pubblicazioni e link utili
Studiare le date dei record
Studia le date principali
Inizio studio
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Altri numeri di identificazione dello studio
- CASE5Y15
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Cancro
-
Zeba Ahmad, Ph.D.American Cancer Society, Inc.ReclutamentoCaregiving for CancerStati Uniti
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletatoAdenocarcinoma dell'intestino tenue | Adenocarcinoma dell'intestino tenue in stadio III AJCC v8 | Adenocarcinoma dell'intestino tenue in stadio IIIA AJCC v8 | Adenocarcinoma dell'intestino tenue in stadio IIIB AJCC v8 | Adenocarcinoma dell'intestino tenue stadio IV AJCC v8 | Ampolla di Vater... e altre condizioniStati Uniti
-
Georgetown UniversityNational Cancer Institute (NCI); American Cancer Society, Inc.; Susan G. Komen...CompletatoStudio delle donne cinesi che non hanno aderito alle linee guida per lo screening mammografico dell'American Cancer SocietyStati Uniti
-
Institut Cancerologie de l'OuestAttivo, non reclutanteQualità della vita al lavoro | Professionisti paramedici | Toccare Massaggio | Cancer CenterFrancia
-
Emory UniversityNational Cancer Institute (NCI)RitiratoCancro al seno in stadio IV prognostico AJCC v8 | Neoplasia maligna metastatica nel cervello | Carcinoma mammario metastatico | Anatomic Stage IV Breast Cancer American Joint Committee on Cancer (AJCC) v8
-
Yonsei UniversityNon ancora reclutamentoRAS/BRAF Wild-Type Advanced Cancer MathementCorea, Repubblica di
-
NRG OncologyNational Cancer Institute (NCI)CompletatoCancro al seno in stadio anatomico IV AJCC v8 | Cancro al seno in stadio IV prognostico AJCC v8 | Neoplasia maligna metastatica nell'osso | Neoplasia maligna metastatica nei linfonodi | Neoplasia maligna metastatica nel fegato | Carcinoma mammario metastatico | Neoplasia maligna metastatica nel... e altre condizioniStati Uniti, Canada, Arabia Saudita, Corea del Sud
-
Jonsson Comprehensive Cancer CenterReclutamentoAdenocarcinoma prostatico | Cancro alla prostata in stadio II AJCC v8 | Fase I Cancro alla prostata American Joint Committee on Cancer (AJCC) v8Stati Uniti
-
Jonsson Comprehensive Cancer CenterNovartis PharmaceuticalsReclutamentoCarcinoma della prostata | Stadio IVB Cancro alla prostata American Joint Committee on Cancer (AJCC) v8Stati Uniti
-
Second Affiliated Hospital, School of Medicine,...Attivo, non reclutanteElettroacopuntura combinata con paclitaxel legato alla proteina e anticorpo PD-1 per il trattamento di seconda linea di HER2 negativo, PMMR/MSS Advanced Gastric CancerCina
Prove cliniche su Standard supportive care
-
RWTH Aachen UniversityBiotestReclutamentoSepsi | Shock settico | PeritoniteGermania, Austria
-
Emory UniversityNational Institute of Nursing Research (NINR)Completato
-
Colorado Prevention CenterCompletatoImplementazione del Vascular Care Team per migliorare la gestione medica dei pazienti affetti da PADMalattia delle arterie perifericheStati Uniti
-
East and North Hertfordshire NHS TrustNon ancora reclutamentoFibrillazione atriale (FA)
-
Summa Therapeutics, LLCNon ancora reclutamentoMalattia arteriosa periferica sotto il ginocchio | Malattia arteriosa periferica, Rutherford 4 e 5 con possibilità di migliorare la vascolarizzazioneStati Uniti
-
Children's Hospital Los AngelesUniversity of Southern California; Cedars-Sinai Medical CenterCompletato
-
University of Alabama at BirminghamCompletato
-
Vrije Universiteit BrusselReclutamento
-
University of Colorado, DenverAssociation of Academic SurgeryReclutamento
-
Western UniversityNon ancora reclutamento